Patients with more CD8+ T cell infiltration in their tumors have better prognosis [9, 10], and studies based on bulk-sequencing of tumor samples followed by computational peptide-class I MHC affinity prediction [11] have associated increased mutations and resulting mutant MHC I peptide ligands with improved survival [12], especially in the context of checkpoint blockade immunotherapy [13, 14]. Here, CD8A is linked to neoplasm.